Format

Send to

Choose Destination
Histol Histopathol. 2014 Feb;29(2):167-75. doi: 10.14670/HH-29.167. Epub 2013 Oct 16.

Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future.

Author information

1
Department of Specialized, Experimental and Diagnostic Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. maggie.nannini@gmail.com.
2
Department of Specialized, Experimental and Diagnostic Medicine, Sant'Orsola-Malpighi Hospital, and "Giorgio Prodi" Cancer Research Center, University of Bologna, Bologna, Italy.
3
"Giorgio Prodi" Cancer Research Center, University of Bologna, Bologna, Italy.

Abstract

In the last decades, the concept that Insulin-like Growth Factor (IGF) axis plays a key role in several steps of tumorigenesis, cancer growth and metastasis has been widely documented. The aberration of the IGF system has been described in many kinds of tumours, providing several lines of evidence in support of IGF receptor type 1 (IGF1R) as molecular target in cancer treatment. Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract, commonly characterized in most cases by KIT and PDGFRA gain mutations. Beyond to the well recognized KIT and PDGFRA gain mutations, in the last years other molecular aberrations have been investigated. Recently, several lines of evidence about the involvement of the IGF system in GIST have been accumulated. The aim of this review is to report all current data about the IGF system involvement in GIST, focusing on the current clinical implication and future perspectives.

PMID:
24129766
DOI:
10.14670/HH-29.167
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sercrisma International S.L.
Loading ...
Support Center